Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Trading Statement

2 Apr 2024 07:00

RNS Number : 9105I
Itaconix PLC
02 April 2024
 

For release: 07.00, 2 April 2024

 

Itaconix plc

("Itaconix" or the "Company")

Trading Update

Itaconix (AIM: ITX) (OTCQB: ITXXF, a leading innovator in sustainable plant-based polymers used to decarbonize everyday consumer products, reports that following extensive negotiation, it has been unable to reach satisfactory commercial terms with one of its major existing merchandizing customers in North America for supply in 2024. This is based on the Board's strategic decision to decline low-margin business and focus on diversifying the revenue base for its performance ingredients. The Company continues to focus on improving gross profit margins and seeks to build a large, profitable specialty ingredients business. Whilst discussions on 2024 pricing and volumes are continuing, and some order volumes remain likely, the impact is likely to be much lower volumes and revenue from this merchandizer in FY 2024 compared to FY 2023.

With the Board's decision, revenues and adjusted EBITDA1 for FY 2024 and FY 2025 are expected to be below management's previous expectations, whilst gross profit margins will improve. FY 2024 revenues are now expected to be in the range of $6.0 million to $6.5 million.

As per the trading update on 27 February 2024, the Company expects to announce final results for FY 2023 in line with current expectations, achieving another record year with unaudited revenues of $7.9 million, a substantial increase of 40.6% over FY 2022 of $5.6 million.

Itaconix remains highly optimistic about the Company's future and commercial progress. The Company is securing new detergent customers in Europe and North America and expanding the use of its performance ingredients into new user bases. These efforts are focused on building a more diverse, profitable, and sustainable revenue base to achieve Itaconix's goal of being a large and profitable specialty ingredient company.

John R. Shaw, CEO of Itaconix, commented:

"Enhancing our revenue structure and increasing gross profit margins, while impacting our near-term revenue streams, pave the way for our next stage of growth. We are positioning ourselves to better capture the commercial value of our performance ingredients with new customer wins, new volumes in non-detergent uses, and important new product development initiatives. I believe the strategic efforts we are taking now will advance our long-term revenue growth and profitability objectives."

 

1 Adjusted for interest, tax, depreciation, amortization, share-based payments, and exceptional items.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

- Ends -

 

Itaconix plc

John R. Shaw / Laura Denner

+1 603 775-4400

Belvedere Communications

John West / Llew Angus

+44 (0)20 7653 8702

Canaccord Genuity - Nominated Adviser and Sole Broker

Adam James / Harry Pardoe

+44 (0) 20 7523 8000

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of products in cleaning, hygiene, and beauty.

www.itaconix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEASLAEDKLEEA
Date   Source Headline
11th May 20157:05 amRNSDirector Declaration
5th May 20157:01 amRNSDirector/PDMR Shareholding
13th Apr 20157:00 amRNSNotice of AGM
30th Mar 20157:00 amRNSPreliminary Results
24th Mar 20157:15 amRNSDirector Declaration
9th Jan 20157:00 amRNSBlocklisting Interim Review
5th Jan 201512:00 pmRNSTotal Voting Rights
11th Dec 20147:00 amRNSHolding(s) in Company
10th Nov 20147:00 amRNSPatent Infringement Settled and Discontinued
10th Oct 20144:22 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSInterim Results
25th Sep 20147:00 amRNSGlobal licence signed with Solvay
26th Aug 20147:00 amRNSNew CEO start date confirmed
9th Jul 20147:00 amRNSBlocklisting Interim Review
4th Jul 20147:00 amRNSAppointment of Chief Executive Officer
2nd Jul 20147:00 amRNSTotal Voting Rights
23rd Jun 20147:01 amRNSNotification of Major Interest in Shares
23rd Jun 20147:00 amRNSNotification of Major Interest in Shares
9th Jun 20147:00 amRNSUS supply agreement for nicotine chewing gum
3rd Jun 20147:00 amRNSTotal Voting Rights
22nd May 201412:34 pmRNSResult of AGM
30th Apr 20143:16 pmRNSNotification of Major Interest in Shares
24th Apr 20147:00 amRNSAward under Long Term Incentive Plan
23rd Apr 201412:45 pmRNSNotification of Major Interest in Shares
23rd Apr 20147:00 amRNSNotice of AGM
22nd Apr 201411:58 amRNSTotal Voting Rights
14th Apr 20147:00 amRNSAward of Technology Strategy Board funding
31st Mar 20147:00 amRNSPreliminary Results
3rd Mar 20147:00 amRNSTotal Voting Rights
30th Jan 201411:39 amRNSBlock Listing
27th Jan 20147:00 amRNSDirectorate Change
24th Jan 20144:46 pmRNSHolding(s) in Company
10th Jan 20147:00 amRNSBlock Listing Six Monthly Return
20th Nov 20137:00 amRNSMarketing approval of nicotine gum in Europe
17th Oct 20137:00 amRNSSupply and Distribution Agreement with Amma Polska
11th Oct 20137:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Sep 20137:00 amRNSInterim Results
1st Aug 20137:00 amRNSTotal Voting Rights
22nd Jul 20137:00 amRNSAward of contract to supply nicotine gum
15th Jul 201312:20 pmRNSChange of Registered Office
9th Jul 20137:00 amRNSBlocklisting Interim Review
28th May 20132:02 pmRNSResult of AGM
17th Apr 20134:47 pmRNSHolding(s) in Company
17th Apr 20137:00 amRNSDirector's Dealings
9th Apr 20137:00 amRNSPositive test results for encapsulation technology
22nd Mar 20137:00 amRNSNotice of AGM and Posting of Annual Report
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 20137:00 amRNSTotal Voting Rights
1st Feb 20132:42 pmRNSNotice of patent infringement proceedings
10th Jan 20137:01 amRNSAwards under Long Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.